35Pharma

GSK 35Pharma Acquisition: Strengthening the Respiratory and Metabolic Pipeline

By BiotechReality Business Intelligence Desk
16 April 2026

GSK has finalized its $950 million acquisition of 35Pharma Inc., securing HS235 a potential best-in-class treatment for pulmonary hypertension with unique metabolic benefits.

Tag: 35Pharma

GSK 35Pharma Acquisition: Strengthening the Respiratory and Metabolic Pipeline

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement